The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin

Aimee DallobMerck, Whitehouse Station, NJ, USA

Wen-Lin LuoMerck, Whitehouse Station, NJ, USA

Julie Mabalot LukMerck, Whitehouse Station, NJ, USA

Lisa RatcliffeMerck, Whitehouse Station, NJ, USA

Amy O. Johnson-LevonasMerck, Whitehouse Station, NJ, USA

Jules I. SchwartzMerck, Whitehouse Station, NJ, USA

Victor DishyDaiichi-Sankyo Pharma Development, Edison, NJ, USA

Walter K. KraftDepartment of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA, USA

Jan N. De HoonCenter for Clinical Pharmacology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium

Anne Van HeckenCenter for Clinical Pharmacology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium

Inge De Lepeleire , Merck, Brussels, Belgium

Waldemar RadziszewskiMerck, Whitehouse Station, NJ, USA

John A. WagnerMerck, Whitehouse Station, NJ, USA

Eseng LaiMerck, Whitehouse Station, NJ, USACorrespondence[email protected]

Your download is now in progress and you may close this window